for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

アステラス製薬株式会社

4503.T

現在値

1,917.00JPY

変化

12.00(+0.63%)

出来高

8,799,000

本日のレンジ

1,909.00

 - 

1,932.00

52週レンジ

1,739.00

 - 

2,205.00

∙ 約20分前の相場を表示しています。

適時開示

Seagen, Astellas Announce Positive Topline Results For PADCEV With KEYTRUDA As First-Line Treatment For Advanced Urothelial Cancer

July 26 (Reuters) - Seagen Inc <SGEN.O>::SEAGEN AND ASTELLAS ANNOUNCE POSITIVE TOPLINE RESULTS FOR PADCEV® (ENFORTUMAB VEDOTIN-EJFV) WITH KEYTRUDA® (PEMBROLIZUMAB) AS FIRST-LINE TREATMENT FOR ADVANCED UROTHELIAL CANCER.COMPANIES PLAN TO DISCUSS RESULTS WITH REGULATORY AUTHORITIES.SEAGEN - RESULTS DEMONSTRATED 64.5% CONFIRMED OBJECTIVE RESPONSE RATE/ BLINDED INDEPENDENT CENTRAL REVIEW, PRIMARY ENDPOINT OF COHORT K.SEAGEN - RESULTS ARE GENERALLY CONSISTENT WITH PREVIOUSLY REPORTED EFFICACY & SAFETY RESULTS OF THE EV-103 DOSE-ESCALATION COHORT, EXPANSION COHORT A.

Generian And Astellas Enter Into Collaboration And Exclusive License Agreement To Discover And Develop Novel Small Molecules For Undruggable Targets

June 29 (Reuters) - Astellas Pharma Inc <4503.T>::GENERIAN AND ASTELLAS ENTER INTO COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT TO DISCOVER AND DEVELOP NOVEL SMALL MOLECULES FOR UNDRUGGABLE TARGETS.GENERIAN PHARMACEUTICALS - CO AND MITOBRIDGE ANNOUNCED TODAY THAT THEY HAVE ENTERED INTO A COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT.GENERIAN PHARMACEUTICALS - IN DEAL, ASTELLAS TO BE RESPONSIBLE FOR CLINICAL DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF JOINT RESEARCH PRODUCTS.GENERIAN PHARMACEUTICALS - WILL RECEIVE UPFRONT PAYMENT, ELIGIBLE TO RECEIVE SUCCESS-BASED MILESTONE PAYMENTS THAT COULD BE OVER $180 MILLION.GENERIAN PHARMACEUTICALS - WILL RECEIVE SINGLE DIGIT ROYALTIES ON GLOBAL NET SALES OF JOINT RESEARCH PRODUCTS.

Astellas And Sutro Biopharma Announce Worldwide Strategic Collaboration To Advance Novel Immunostimulatory Antibody-Drug Conjugates

June 27 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS AND SUTRO BIOPHARMA ANNOUNCE WORLDWIDE STRATEGIC COLLABORATION TO ADVANCE NOVEL IMMUNOSTIMULATORY ANTIBODY-DRUG CONJUGATES (IADCS).SUTRO BIOPHARMA INC - WILL RECEIVE AN UPFRONT PAYMENT OF US$90 MILLION TO DEVELOP IADCS FOR THREE BIOLOGICAL TARGETS.SUTRO - MAY BE ELIGIBLE TO RECEIVE UP TO ADDITIONAL $422.5 MILLION IN MILESTONES FOR EACH PRODUCT CANDIDATE PLUS ROYALTIES.

Astellas Announces FDA Update On The Fortis Clinical Trial Of At845 In Adults With Late-Onset Pompe Disease

June 26 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS ANNOUNCES FDA UPDATE ON THE FORTIS CLINICAL TRIAL OF AT845 IN ADULTS WITH LATE-ONSET POMPE DISEASE.ASTELLAS PHARMA - US FDA HAS PLACED A CLINICAL HOLD ON FORTIS PHASE 1/2 TRIAL FOLLOWING OCCURRENCE OF A SERIOUS ADVERSE EVENT.SERIOUS ADVERSE EVENT (SAE) OF PERIPHERAL SENSORY NEUROPATHY IN ONE OF TRIAL PARTICIPANTS.FDA INFORMED ASTELLAS THAT IT DID NOT HAVE SUFFICIENT INFORMATION TO ASSESS RISKS TO SUBJECTS.ALL CURRENTLY ENROLLED PARTICIPANTS WILL CONTINUE TO BE MONITORED CLOSELY PER STUDY PROTOCOL.ASTELLAS IS REVIEWING POTENTIAL FINANCIAL IMPACTS OF THIS MATTER FOR FISCAL YEAR ENDING MARCH 31, 2023.

Astellas Submits Fezolinetant New Drug Application To U.S. FDA

June 24 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS SUBMITS FEZOLINETANT NEW DRUG APPLICATION TO U.S. FDA.

Astellas Pharma Inc To Book Impairment Loss Of About 50 Billion Yen In Q4

April 22 (Reuters) - Astellas Pharma Inc <4503.T>::TO BOOK IMPAIRMENT LOSS OF ABOUT 50 BILLION YEN ($390 million) IN Q4.TO BOOK IMPAIRMENT LOSS OF INTANGIBLE ASSETS OF $170 MILLION IN Q1 FY2022.FY2021 Q4 IMPAIRMENT LOSS RELATED TO ASPIRO CLINICAL TRIAL, TERMINATION OF DEVELOPMENT OF DNA VACCINE ASP2390 AND GITR AGONISTIC ANTIBODY ASP1951.FY2022 Q1 IMPAIRMENT LOSS RELATED TO TERMINATION OF GENE THERAPY PROGRAMS AT702, AT751 AND AT753 FOR DUCHENNE MUSCULAR DYSTROPHY.

Astellas Announces Topline Results From Long-Term Phase 3 Safety Study Of Fezolinetant

March 7 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS ANNOUNCES TOPLINE RESULTS FROM LONG-TERM PHASE 3 SAFETY STUDY OF FEZOLINETANT WHICH INFORM FUTURE REGULATORY FILINGS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE.ASTELLAS PHARMA INC - PRIMARY ENDPOINT ASSESSING ENDOMETRIAL HEALTH WAS ACHIEVED.ASTELLAS PHARMA INC - MOST COMMON TREATMENT EMERGENT ADVERSE EVENTS (TEAE) WERE HEADACHE AND COVID-19, CONSISTENT WITH PLACEBO.

Astellas Pharma: Affinivax Reacquires Rights From Astellas For ASP3772, A Novel 24-Valent Streptococcus Pneumoniae Vaccine Candidate From Affinivax’S Maps Platform

March 1 (Reuters) - Astellas Pharma Inc <4503.T>::AFFINIVAX REACQUIRES RIGHTS FROM ASTELLAS FOR ASP3772, A NOVEL 24-VALENT STREPTOCOCCUS PNEUMONIAE VACCINE CANDIDATE FROM AFFINIVAX’S MAPS PLATFORM.ASTELLAS WILL RECEIVE A $65 MILLION UPFRONT PAYMENT AND WILL BE ELIGIBLE TO RECEIVE MILESTONE PAYMENTS AND ROYALTIES TIED TO THE CLINICAL DEVELOPMENT AND COMMERCIALIZATION OF ASP3772.TRANSACTION EXPECTED TO CLOSE IN MARCH OR APRIL.

Astellas Pharma Inc Says To Buy Back Up To 1.57% Of Own Shares Worth 50 Billion Yen

Feb 2 (Reuters) - Astellas Pharma Inc <4503.T>::ASTELLAS PHARMA INC SAYS TO BUY BACK UP TO 1.57% OF OWN SHARES WORTH 50 BILLION YEN.

Seagen Says Japan’S MHLW Approves Padcev (Enfortumab Vedotin) For Advanced Urothelial Cancer

Sept 27 (Reuters) - :JAPAN’S MHLW APPROVES PADCEV® (ENFORTUMAB VEDOTIN) FOR ADVANCED UROTHELIAL CANCER.SEAGEN INC - APPROVAL IS PRIMARILY BASED ON GLOBAL PHASE 3 EV-301 CLINICAL TRIAL, WHICH INCLUDED SITES IN JAPAN.SEAGEN INC - NEW DRUG APPLICATION RECEIVED PRIORITY REVIEW.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up